ProfileGDS5678 / 1421819_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 96% 95% 96% 95% 96% 96% 96% 96% 96% 96% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.4916295
GSM967853U87-EV human glioblastoma xenograft - Control 28.7824696
GSM967854U87-EV human glioblastoma xenograft - Control 38.6810695
GSM967855U87-EV human glioblastoma xenograft - Control 49.0554596
GSM967856U87-EV human glioblastoma xenograft - Control 58.6677195
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.516896
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.5169896
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.8235196
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.8086196
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.8659396
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.8362396
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.9716396
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.024496
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.8465396